Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Praveen K BommareddyHiroaki WakimotoRobert L MartuzaHoward L KaufmanSamuel D RabkinDipongkor SahaPublished in: Journal for immunotherapy of cancer (2024)
Our findings illustrate that G47Δ-mIL2 is efficacious, stimulates antitumor immunity against orthotopic GBM, and may also target GSC. OHSV expressing IL-2 may represent an agent that merits further exploration in patients with GBM.